INTRODUCTION
============

Macrophages (Mϕ) represent a ubiquitous yet complex and nuanced population of immune cells that play essential roles in both disease and homeostasis throughout the body ([@b58-molcell-37-4-275-1]). In addition to monocytes and Mϕ circulating throughout the bloodstream, specialized tissue-resident Mϕ can be found in most major organs, including Kupffer cells in the liver, Langer-hans cells in the skin, microglia in the brain, splenic red pulp Mϕ, lung alveolar Mϕ, adipose tissue Mϕ, and bone osteoclasts, to name a few ([@b26-molcell-37-4-275-1]; [@b42-molcell-37-4-275-1]; [@b60-molcell-37-4-275-1]; [@b157-molcell-37-4-275-1]). While some identify these populations as the endpoint of bone marrow monocyte maturation, several lines of evidence indicate that tissue resident Mϕ originate during embryogenesis in association with their specific tissue independently from blood monocytes and monocytes/Mϕ recruited to sites of inflammation ([@b26-molcell-37-4-275-1]; [@b47-molcell-37-4-275-1]; [@b122-molcell-37-4-275-1]). Regardless of their location, Mϕ are responsible for the maintenance of healthy tissues through phagocytic clearance of apoptotic cells and foreign materials and through tissue repair and remodeling during wound healing ([@b31-molcell-37-4-275-1]; [@b43-molcell-37-4-275-1]; [@b81-molcell-37-4-275-1]; [@b83-molcell-37-4-275-1]). Mϕ are also major regulators of the inflammatory response to disease and infection, acting as a bridge between innate and adaptive immunity by monitoring the microenvironment through an array of surface receptors and secreting appropriate cytokines and chemokines ([@b54-molcell-37-4-275-1]; [@b123-molcell-37-4-275-1]).

Depending on the stimuli they encounter, tissue resident and circulatory Mϕ populations can be directed to distinct phenotypic programs in a process known as Mϕ polarization ([Fig. 1](#f1-molcell-37-4-275-1){ref-type="fig"}, [Table 1](#t1-molcell-37-4-275-1){ref-type="table"}). The diverse properties of different Mϕ subsets can have drastic effects on health and disease within the tissues where they reside; while the induction of a particular subset can be protective during homeostasis or disease, this process can be altered or subverted to enhance pathogenesis and disease progression (by, for example, inappropriately dampening the immune response or exacerbating harmful inflammation) ([@b95-molcell-37-4-275-1]). Therefore, this review aims to summarize recent findings regarding the identity, properties, and roles of polarized Mϕ in various disease models and the development of therapeutic strategies that target both the process of Mϕ polarization and individual Mϕ subsets.

PHENOTYPIC POLARIZATION OF MΦ
=============================

The most well-described and commonly reported paradigm of Mϕ polarization is the M1/M2 polarization axis ([@b82-molcell-37-4-275-1]; [@b85-molcell-37-4-275-1]; [@b130-molcell-37-4-275-1]). Originally named to reflect relationships to Th1/Th2 polarization of immune responses, M1 and M2 Mϕ are also referred to as classically or alternatively activated Mϕ, respectively ([@b48-molcell-37-4-275-1]; [@b87-molcell-37-4-275-1]).

Classical activation is stimulated by microbial products and proinflammatory cytokines (IFNγ and/or LPS or TNF), and the resulting M1 Mϕ are characterized by high antigen presentation, high production of IL-12 and IL-23, and high production of nitric oxide (NO) and reactive oxygen intermediates (ROI) ([@b147-molcell-37-4-275-1]). M1 Mϕ have been shown to produce several other inflammatory cytokines like TNFα; IL-1, -6, and -12; Type I IFN; CXCL1-3, 5 and 8--10; CCL2-5 and 11; CXCL16; and CX3CL1 ([@b82-molcell-37-4-275-1]; [@b128-molcell-37-4-275-1]).

By contrast, alternative/M2 activation is mediated by IL-4, IL-10, and IL-13, which were initially thought to produce "deactivated Mϕ" ([@b85-molcell-37-4-275-1]). M2 Mϕ are marked by the upregulation of several surface molecules including Dectin-1, DC-SIGN, mannose receptor (MRC1/CD206), scavenger receptor A (CD204), scavenger receptor B-1, CD163, CCR2, CXCR1, and CXCR2 ([@b48-molcell-37-4-275-1]; [@b82-molcell-37-4-275-1]; [@b85-molcell-37-4-275-1]). M2 Mϕ exhibit altered cytokine and chemokine production, and typically produce high levels of IL-10 and low levels of IL-12 ([@b93-molcell-37-4-275-1]). CCL1, CCL2, CCL17, CCL18, CCL22, CCL24, and IL-1Ra are also made by alternatively activated Mϕ ([@b82-molcell-37-4-275-1]). Genetic studies of M2 Mϕ in mouse models have identified additional signatures of alternative activation, including arginase 1 (Arg1), YM1 (a member of the chitinase family) and FIZZ1 (found in inflammatory zone 1, RETNLA) ([@b112-molcell-37-4-275-1]; [@b113-molcell-37-4-275-1]). Generally, the M2 polarization state is characterized by little to no secretion of proinflammatory cytokines, increased secretion of anti-inflammatory cytokines, enhanced scavenging of cellular debris, promotion of tissue remodeling and repair, and, in some cases, increased capacity to fight parasitic infections ([@b1-molcell-37-4-275-1]). Additionally, the concept of resolution of inflammation has evolved and is no longer perceived as a passive process that simply occurs when the insult disappears, but rather as a highly orchestrated response coordinated by a complex regulatory network of cells and anti-M1 mediators called pro-resolving mediators ([@b116-molcell-37-4-275-1]).

M2 Mϕ can be further divided into subtypes according to their inductive stimuli and secreted chemokines ([@b84-molcell-37-4-275-1]). M2a Mϕ are stimulated by IL-4 and IL-13 and produce CCL24, CCL22, CCL17, and CCL18, which are recognized by CCR3, CCR4, and CCR8 and promote recruitment of eosinophils, basophils, and Th2 cells. M2b Mϕ result from activation with immune complexes and TLR agonists (like LPS) and produce CCL1, which recruits Tregs. IL-10 drives Mϕ polarization to M2c cells, which produce CCL16 and 18, recruiting eosinophils and naïve T cells, respectively. M2d Mϕ accumulate in the tumor microenvironment and present an IL-10^hi^VEGF^hi^ M2 profile, but also exhibit some M1 characteristics such as expression of INFγ-inducible chemokines CCL5, CXCL10, and CXCL16 ([@b32-molcell-37-4-275-1]).

A full understanding of the M1/M2 paradigm of Mϕ polarization, however, contains some caveats. First, M1 and M2 Mϕ as defined in the foundational literature most likely do not exist as distinct categories, but rather should be considered as extremes at either end of a continuum of overlapping functional states ([@b94-molcell-37-4-275-1]). Indeed, Mϕ with combinations of M1 and M2 markers can be found in atherosclerotic plaques and some murine tumors ([@b62-molcell-37-4-275-1]; [@b146-molcell-37-4-275-1]). Second, unlike the irreversible phenotypic changes seen in lymphocytes after exposure to polarizing cytokines, Mϕ polarization is both transient and plastic ([@b7-molcell-37-4-275-1]; [@b9-molcell-37-4-275-1]; [@b130-molcell-37-4-275-1]; [@b136-molcell-37-4-275-1]). For example, M2 Mϕ can be reprogrammed to express M1 genes following exposure to TLR ligands or IFNγ ([@b96-molcell-37-4-275-1]; [@b135-molcell-37-4-275-1]). Finally, while there is partial overlap of M1- and M2-identifying markers in murine and human studies, there are still markers in each system that fail to translate to the other. The chitinase-like proteins YM1 and YM2, along with FIZZ1, are markers of murine M2 polarization which lack human orthologs, while CCL14, CCL18, and CCL23 are human-restricted M2 markers with no murine orthologs ([@b19-molcell-37-4-275-1]; [@b85-molcell-37-4-275-1]; [@b112-molcell-37-4-275-1]). Finally, there are other specially activated Mϕ (M4, Mhem, and Mox) that have been described in atherosclerosis and may lie on a separate activation axis from M1/M2 Mϕ ([Fig. 1](#f1-molcell-37-4-275-1){ref-type="fig"}). These atherosclerotic Mϕ subsets have been discussed in recent reviews ([@b37-molcell-37-4-275-1]; [@b72-molcell-37-4-275-1]), but will not be examined in detail here.

SIGNALING PATHWAYS INVOLVED IN MΦ POLARIZATION
==============================================

The network of molecular mediators that regulate M1/M2 polarization in response to various stimuli is incompletely understood, but several signaling pathways have been implicated in this process ([Fig. 2](#f2-molcell-37-4-275-1){ref-type="fig"}). One of the major pathways identified is the JAK/STAT pathway, which mediates responses to a collection of different cyotkines and growth factors and regulates processes from hematopoiesis and immune development to lactation and adipogenesis ([@b115-molcell-37-4-275-1]). Binding of IFNγ to its cell surface receptor leads to activation of receptor-associated JAKs, which in turn cause STAT1 to dimerize and translocate to the nucleus where it initiates transcription of genes that promote M1-associated functions like enhanced microbicidal activity and proinflammatory cytokine production ([@b56-molcell-37-4-275-1]; [@b114-molcell-37-4-275-1]). Mϕ-specific deletion of SOCS3, an inhibitor of cytokine and JAK/STAT signaling, was found to increase levels of the M1 genes IL-1β, IL-6, IL-12, IL-23, and iNOS ([@b109-molcell-37-4-275-1]) and increase phosphorylation of STAT1 and STAT3 ([@b110-molcell-37-4-275-1]).

In contrast, STAT6 is activated by IL-4 and IL-13 to induce M2 polarization ([@b25-molcell-37-4-275-1]; [@b92-molcell-37-4-275-1]; [@b134-molcell-37-4-275-1]). C-Jun N-terminal kinase (JNK), a mitogen-activated protein kinase (MAPK) involved in cell proliferation, transformation, differentiation, and apoptosis is likely involved in this pathway ([@b160-molcell-37-4-275-1]). Upon activation, JNK can phosphorylate serine 707 on STAT6, thereby deactivating it ([@b127-molcell-37-4-275-1]). A study of Mϕ polarization in obesity showed that mice lacking the JNK activator MLK3 were also deficient in M1 Mϕ polarization ([@b41-molcell-37-4-275-1]). The transcription factors PPARγ and PPARδ are activated by STAT6 and necessary for M2 polarization, and PPARδ^−/−^ Mϕ exhibit enhanced activation of JNK following treatment with adipocyte-conditioned medium, which contains the M2 cytokines IL-4 and IL-13 ([@b63-molcell-37-4-275-1]; [@b102-molcell-37-4-275-1]). The zinc-finger transcriptional regulator Krüppel-like factor 4 (KLF4) is involved in this pathway as well and cooperates with STAT6 to skew polarization towards M2 by sequestering coactivators of NF-κB ([@b74-molcell-37-4-275-1]).

Furthermore, the phosphoinositol-3-kinase (PI3K) signaling pathway, which activates multiple kinase cascades through the production of the second messenger PIP3, regulates Mϕ survival and gene expression *via* activation of the Akt family of serine/threonine protein kinases ([@b75-molcell-37-4-275-1]; [@b80-molcell-37-4-275-1]). Knockout studies have demonstrated that M1 polarization depends on the activation of Akt2 while M2 polarization requires Akt1 ([@b2-molcell-37-4-275-1]). In addition, the PI3K/Akt signaling pathway controls the activation of mTOR, which promotes M2 polarization ([@b12-molcell-37-4-275-1]; [@b86-molcell-37-4-275-1]; [@b150-molcell-37-4-275-1]).

Interferon-regulatory factor (IRF) proteins are also regulators of Mϕ polarization. IRF5 is associated with M1 polarization and promotes the transcription of genes encoding IL-12 while repressing the gene that encodes IL-10 ([@b69-molcell-37-4-275-1]). Notch signaling through the nuclear transducer RBP-J controls expression of IRF8, which induces M1 gene expression ([@b154-molcell-37-4-275-1]). IRF4 is highly expressed in adipose tissue Mϕ (ATM) and its deletion leads to increased production of IL-1β and TNFα and expression of M1 markers, indicating that IRF4 activation contributes to M2 polarization ([@b34-molcell-37-4-275-1]). The IRFs also underlie the ability of GM-CSF and M-CSF to induce polarization: GM-CSF leads to downstream activation of IRF5 (M1) while M-CSF leads to IRF4 (M2) activation ([@b71-molcell-37-4-275-1]).

BACTERIAL INFECTIONS
====================

Given the ability of Mϕ to acquire enhanced microbicidal abilities following stimulation with microbial products and the preeminent roles of Mϕ in both innate and adaptive immune responses, one might predict that pathogens would evolve strategies to redirect and alter Mϕ activation in their favor. Several transcriptome analysis studies have established that innate immune cells, particularly Mϕ, engage in a common response to pathogen challenge that involves a shared pattern of gene expression ([@b59-molcell-37-4-275-1]; [@b97-molcell-37-4-275-1]). A multi-study review of transcriptional responses of mononuclear phagocytes to bacteria and bacterial components focusing specifically on genes involved in Mϕ polarization identified a common response program that mainly involved the upregulation of M1-associated genes, including the cytokines TNF, IL-6, IL-12, IL-1β, the cytokine receptors IL-7R and IL-15RA, the chemokines CCL2, CCL5, and CXCL8, and the chemokine receptor CCR7 ([@b5-molcell-37-4-275-1]). This M1 activation program is typically associated with protection against disease, and M1 polarization has been shown to aid host control of several bacteria, including *Listeria monocytogenes*, *Salmonella typhimurium*, *Mycobacterium tuberculosis*, *Mycobacterium ulcerans*, and *Chlamydia* infections ([@b5-molcell-37-4-275-1]; [@b17-molcell-37-4-275-1]; [@b61-molcell-37-4-275-1]; [@b66-molcell-37-4-275-1]; [@b119-molcell-37-4-275-1]; [@b126-molcell-37-4-275-1]).

Consequently, several pathogenic bacteria, especially intracellular species, have developed mechanisms to interfere with Mϕ polarization in order to enhance their own survival. Some species accomplish this by blunting M1 polarization to reduce inflammation and microbicidal functions of Mϕ. The intracellular form of the enteropathogen *Shigella flexneri* produces an altered, hypoacetylated form of LPS that evades recognition by TLR4 and elicits decreased production of proinflammatory cytokines from murine bone marrow derived Mϕ (BMDM) ([@b105-molcell-37-4-275-1]). During pulmonary infection in mice, *Staphylococcus aureus* induces Akt1 signaling to enhance SOCS1 activity and inhibit NF-κB activity, shifting Mϕ from an antimicrobial M1 phenotype to a functionally inert one ([@b155-molcell-37-4-275-1]). *M. tuberculosis* secretes the virulence factors lipoarabinomannan and early secretory antigenic target-6 (ESAT-6), which inhibit M1 activation by inhibiting phagosome maturation and NF-κB activation, respectively ([@b77-molcell-37-4-275-1]). *M. tuberculosis* also subverts the inflammatory response by stimulating Wnt6 signaling in infected Mϕ in granulomatous lesions in the lung, driving M2-like polarization ([@b120-molcell-37-4-275-1]). *S. aureus* biofilms are resistant to Mϕ invasion, but those Mϕ that do successfully penetrate catheter-associated biofilms *in vitro* display decreased expression of IL-1β, TNFα, and iNOS expression but robust Arg1 expression, signifying an M2 profile ([@b143-molcell-37-4-275-1]). *S. typhimurium* has been shown to preferentially associate with M2 Mϕ, and PPARδ expression is upregulated in *Salmonella*-infected Mϕ while PPARδ deficiency severely inhibits bacterial replication and persistence ([@b35-molcell-37-4-275-1]). Interestingly, the dependency of *S. typhimurium* on PPARδ expression was shown to be due to its metabolic effects rather than its ability to reduce production of antimicrobial mediators by promoting M2 polarization, and it remains to be determined whether *S. typhimurium* directly augments PPARδ activity to promote persistence.

VIRAL INFECTIONS
================

Similar to evasion strategies employed by bacterial pathogens, many viruses take advantage of the Mϕ polarization system to enhance their own growth and virulence. However, unlike bacterial pathogens, which generally tend to thrive within and encourage production of M2-polarized Mϕ, viral pathogens more commonly activate M1 polarization. This inflammatory phenotype is often correlated with disease severity. Hepatitis C virus preferentially infects hepatocytes and establishes a chronic inflammatory infection, often leading to fibrotic cirrhosis and hepatocellular carcinoma (HCC) ([@b70-molcell-37-4-275-1]). It has been demonstrated that the viral protein NS3 enhances IL-12 and TNFα production by THP-1 Mϕ, implicating M1 polarization in sustaining inflammation ([@b49-molcell-37-4-275-1]). Furthermore, activation of Mϕ with TLR agonists triggers the secretion of TNFα, which promotes HCV entry into polarized hepatoma cells by relocalizing the tight junction protein and HCV entry factor occludin ([@b38-molcell-37-4-275-1]). Of the three common clades of avian H5N1 influenza virus circulating in poultry in China (2.3.2, 2.3.4, and 7), clade 2.3.4 is the most successful at infecting, replicating within, and inducing cytopathic effects in human monocyte-derived Mϕ (MDM) ([@b138-molcell-37-4-275-1]). H5N1 clade 2.3.4 also stimulated the highest expression of IL-1β, IL-6, IL-8, TNFα, IFNγ, and MCP-1 in MDMs ([@b138-molcell-37-4-275-1]). M2 Mϕ polarization by *S. aureus*, which is commonly present among the airway mucosal microbiota, inhibits influenza-mediated lung injury, implying that M1 Mϕ exacerbate flu infection ([@b149-molcell-37-4-275-1]).

Nonetheless, some viruses do benefit by skewing Mϕ polarization towards an M2 phenotype. During infection by severe acute respiratory syndrome coronavirus (SARS-CoV), lung damage resulting from both intrinsic viral infection and dysregulation of the host immune response rapidly progresses to diffuse alveolar damage, resulting in acute respiratory distress syndrome and pulmonary fibrosis ([@b40-molcell-37-4-275-1]; [@b107-molcell-37-4-275-1]). A recent study revealed that SARS-CoV-infected mice lacking hematopoeitic STAT1 expression have greater weight loss and lung pathology associated with upregulation of the M2 indicators YM1, FIZZ1, IL-4, and IL-13 ([@b106-molcell-37-4-275-1]). Absence of lung disease and prefibrotic lesions in infected STAT1/STAT6^−/−^ double-knockout mice also supported the notion that M2 Mϕ contribute to SARS-CoV pathogenesis. Human cytomegalovirus (HCMV) has a more complex relationship with Mϕ polarization. The HCMV gene UL111A encodes a homolog of human IL-10 that is capable of polarizing monocytes towards an anti-inflammatory M2c phenotype including high expression of the scavenger receptor CD163, suppression of MHC expression, and exppression of heme oxygenase 1 (which suppresses TNFα and IL-1β) ([@b3-molcell-37-4-275-1]). Additionally, HCMV optimally infects M2-but not M1-polarized Mϕ and late-phase HCMV infection is dependent on the M2-promoting activation of mTOR ([@b108-molcell-37-4-275-1]). Despite this, HCMV-activated Mϕ have been shown to adopt an M1 transcriptome profile ([@b18-molcell-37-4-275-1]). HIV-1 similarly seems to benefit from M2 polarization: HIV-1 displays impaired viral DNA synthesis, delayed proviral integration, and reduced proviral transcription in M1 Mϕ, while the M2a surface receptor DC-SIGN facilitates HIV-1 entry, DNA synthesis, and transmission from infected Mϕ to CD4^+^ T cells ([@b14-molcell-37-4-275-1]; [@b15-molcell-37-4-275-1]; [@b16-molcell-37-4-275-1]). Notably, clathrin-mediated endocytosis of HIV-1 is increased in M1 and decreased in M2 Mϕ, but this method of endocytosis leads to increased viral degradation and is unlikely to result in productive infection ([@b45-molcell-37-4-275-1]). Yet, like HCMV, HIV-1 infection of MDMs drives them toward M1 polarization, and the viral protein Nef is preferentially taken up by M2 Mϕ and stimulates an M2-to-M1 transition ([@b15-molcell-37-4-275-1]; [@b20-molcell-37-4-275-1]; [@b77-molcell-37-4-275-1]). These contradictions may be explained by a viral survival strategy that takes advantage of both M1 and M2 Mϕ as means to different ends: M2 Mϕ as a reservoir of replication and M1 Mϕ to recruit fresh immune cells to spread the infection. This can also be inferred from the ability of proinflammatory cytokines and chemokines from HCMV-infected Mϕ to enhance virus replication and dissemination ([@b1-molcell-37-4-275-1]; [@b131-molcell-37-4-275-1]; 2004b).

DIABETES, OBESITY, AND NON-ALCOHOLIC STEATOHEPATITIS
====================================================

Type 1 diabetes is an autoimmune disease that results in high blood sugar following the destruction of insulin-producing pancreatic beta cells *via* activation of innate immunity and expansion of auto-reactive T cells and autoantibody-producing B cells. Monocytes/Mϕ from patients with Type 1 diabetes present a proinflammatory profile (high levels of TNFα, IL-6 and IL-1β) when compared to normal subjects ([@b10-molcell-37-4-275-1]; [@b28-molcell-37-4-275-1]; [@b125-molcell-37-4-275-1]). Moreover, elevated levels of glucose and islet amyloid polypeptide (IAPP) deposition lead to the activation of TLRs and inflammasomes, resulting in beta cell death and decreased insulin secretion ([@b52-molcell-37-4-275-1]). Recently, it has been suggested that M1 Mϕ may contribute to diabetes-related complications such as cardiovascular diseases by altering the immune system of type 1 diabetics ([@b11-molcell-37-4-275-1]). Furthermore, the sustained increase of growth hormone in murine models of type 1 diabetes leads to a reduction of diabetes symptoms by attenuating the apoptosis and increasing the expansion of beta cells ([@b148-molcell-37-4-275-1]). Growth hormone also triggers M2 polarization of Mϕ *via* modulation of the cytokine milieu, stimulating the activity of suppressor T cells and limiting Th17 cell activation ([@b148-molcell-37-4-275-1]).

Obesity is a major health problem in western countries and a risk factor for insulin resistance, type 2 diabetes, hepatic steatosis, and artherosclerosis. Obesity is closely associated with chronic inflammation in adipose tissues, suggesting that the chronic excess of nutrients triggers an immune response in adipose tissues ([@b46-molcell-37-4-275-1]; [@b55-molcell-37-4-275-1]; [@b64-molcell-37-4-275-1]). White adipose tissues store energy in the form of fat and regulate systemic metabolism through the release of adipokines by adipocytes that control insulin sensitivity in the liver and skeletal muscle ([@b137-molcell-37-4-275-1]; [@b141-molcell-37-4-275-1]). In lean subjects and mice, adipose tissue Mϕ (ATM) present an M2 phenotype and are critical to maintaining insulin sensitivity in adipocytes through IL-10 production ([@b74-molcell-37-4-275-1]; [@b78-molcell-37-4-275-1]; [@b79-molcell-37-4-275-1]). In metabolic homeostasis, M2 ATMs are maintained by IL-4 and IL-13 secreted by adipocytes in a PPARγ/δ/β-and KLF4-dependent manner ([@b153-molcell-37-4-275-1]; [@b160-molcell-37-4-275-1]). In obese subjects and mice, adipocytes release proinflammatory mediators (i.e. CCL2/MCP-1, TNFα, CCL5, CCL8 and free fatty acid), promoting the infiltration of Ly6C^hi^ inflammatory monocytes which differentiate into M1-polarized ATMs that express high levels of TNFα, iNOS, IL-6 and IL-1β ([@b21-molcell-37-4-275-1]; [@b78-molcell-37-4-275-1]; [@b103-molcell-37-4-275-1]; [@b141-molcell-37-4-275-1]; [@b151-molcell-37-4-275-1], [@b152-molcell-37-4-275-1]). Therefore, the severity of obesity-related metabolic dysfunctions correlates with M1 ATM infiltration whereas chronic inflammation in adipose tissue inhibits the production of adiponectin, thus contributing to the development of insulin resistance in surrounding adipocytes ([@b78-molcell-37-4-275-1]; [@b151-molcell-37-4-275-1]; [@b152-molcell-37-4-275-1]).

Recently NAFLD (Non-alcoholic fatty liver disease) has emerged as an obesity-related health problem characterized by steatosis (accumulation of lipids in hepatocytes). Hepatic steatosis can evolve to non-alcoholic steatohepatitis (NASH) when accompanied by liver injury (ballooning hepatocytes) and hepatic inflammation, which may be associated with fibrosis and eventually culminates in cirrhosis and HCC. The development of the complex pathology of NASH involves a variety of liver cells including hepatocytes, hepatic Mϕ, and stellate cells. Inflammatory mediators, especially those derived from adipose tissues, the gut, and the liver, have recently been reported to play a major role in initiating and controlling the progression of NASH by regulating lipid metabolism ([@b27-molcell-37-4-275-1]; [@b111-molcell-37-4-275-1]; [@b144-molcell-37-4-275-1]). In particular, the activation of innate immune cells such as Kupffer cells and infiltrating blood-derived monocytes is a major event of NASH development. In homeostatic conditions, Kupffer cells perform immune surveillance by removing pathogens and toxins from the circulation and maintain liver tolerance through IL-10 secretion ([@b142-molcell-37-4-275-1]). Kupffer cells communicate with a variety of hepatic immune cells and interact directly with hepatocytes passing through the space of Disse ([@b111-molcell-37-4-275-1]). In early mouse models of diet-induced steatohepatitis, Kupffer cells are the first innate cells responding to injured hepatocytes and differentiate toward M1 Mϕ, promoting the recruitment of blood-derived CD11b^int^ Ly6C^hi^ monocytes through secretion of TNF~α~ and chemokines (MCP-1 and IP-10) ([@b145-molcell-37-4-275-1]). The recruitment of these inflammatory M1-polarized Ly6C^+^ blood-derived monocytes is dependent of CCR2 and MCP1 ([@b65-molcell-37-4-275-1]; [@b67-molcell-37-4-275-1]; [@b89-molcell-37-4-275-1]; [@b101-molcell-37-4-275-1]). The hallmarks of NASH (i.e. steatosis, low-grade inflammation, and hepatic recruitment of M1-polarized Mϕ) are reduced/delayed following specific depletion of Kupffer cells or by silencing of TNFα in myeloid cells ([@b145-molcell-37-4-275-1]). Moreover, M1-polarized Kupffer cells also produce inflammatory mediators such as IL-1β and ROS, which induce hepatic steatosis and fibrosis ([@b89-molcell-37-4-275-1]; [@b123-molcell-37-4-275-1]). NF-κB and JNK activation in Kupffer cells may contribute to the development of hepatic inflammation by promoting M1-like Mϕ polarization ([@b160-molcell-37-4-275-1]).

Liver Mϕ are also implicated in the severity of NASH *via* the expression of Toll-like receptors (TLR2, TLR4, TLR9, MyD88) and scavenger receptors (scavenger receptor A and CD36) ([@b6-molcell-37-4-275-1]; [@b88-molcell-37-4-275-1]; [@b89-molcell-37-4-275-1]; [@b90-molcell-37-4-275-1]). TLRs and scavenger receptors trigger proinflammatory responses following recognition of hepatic free fatty acids, damage-associated molecular pattern (DAMPs) expressed by steatotic hepatocytes, and/or bacterial products derived from the gut ([@b36-molcell-37-4-275-1]; [@b117-molcell-37-4-275-1]). NASH patients show increased intestinal permeability, resulting in greater hepatic abundance of bacterial products and other TLR ligands derived from the gut *via* portal vein circulation ([@b161-molcell-37-4-275-1]). The imbalance of gut flora may influence liver disease by activating TLRs expressed on liver cells and leading to the activation of NLPR3 ([@b24-molcell-37-4-275-1]; [@b36-molcell-37-4-275-1]; [@b52-molcell-37-4-275-1]; [@b117-molcell-37-4-275-1]). In models of diet-induced NASH and obesity, inflammasome-deficient mice develop more severe NASH which is fully transferable to WT mice upon prolonged cohousing, suggesting that commensal bacteria in the GI tract play an important role in NASH disease progression ([@b24-molcell-37-4-275-1]; [@b51-molcell-37-4-275-1]; 2013; [@b151-molcell-37-4-275-1]).

CANCER
======

Mϕ are a highly influential cell type in most varieties of cancer and are recruited to all solid tumors ([@b13-molcell-37-4-275-1]). The contributions of different subsets of polarized Mϕ to the tumor microenvironment and cancer progression are therefore a subject of great interest. M1 Mϕ are generally considered to be beneficial to the host, and peritumoral Mϕ that express M1 cytokines like IFNγ, IL-1β, and IL-6 have been shown to have antitumoral effects and are associated with improved prognoses ([@b33-molcell-37-4-275-1]; [@b68-molcell-37-4-275-1]; [@b99-molcell-37-4-275-1]; [@b100-molcell-37-4-275-1]; [@b159-molcell-37-4-275-1]). M1 Mϕ may have the opposite effect in virally induced cancers, however: administration of IFNγ or TNFα to patients infected with Kaposi sarcoma virus enhances disease progression ([@b91-molcell-37-4-275-1]). Proinflammatory Mϕ are also harmful in intraocular tumors, where TNFα- and iNOS-dependent antitumor responses lead to necrosis of bystander cells and destruction of the eye ([@b23-molcell-37-4-275-1]).

M2-polarized tumor-associated Mϕ (TAM), on the other hand, have been repeatedly and consistently associated with unfavorable effects like tumor growth, angiogenesis, and metastasis in malignant cancers ([@b1-molcell-37-4-275-1]). The M2 cytokines IL-4, IL-13, and IL-10 are present within the tumor microenvironment and TAMs from various cancer models have been shown to express an M2 activation profile that includes enhanced expression of CD163, MRC-1, c-type lectins, IL-10, and Arg-1 and decreased production of IL-12 ([@b4-molcell-37-4-275-1]; [@b8-molcell-37-4-275-1]; [@b121-molcell-37-4-275-1]; [@b129-molcell-37-4-275-1]). The small secretory lectin Reg3β is an important inhibitor of inflammation in pancreatic and intestinal tissues, and deficiency of Reg3β (an activator of the STAT3 pathway) drastically impairs pancreatic tumor growth by skewing Mϕ polarization away from M2 and towards M1 ([@b44-molcell-37-4-275-1]). M2 TAMs have also been shown to increase fibroblastic morphology, vimentin and snail expression, metalloproteinase activity, and proliferation and migration of pancreatic cancer cells, implicating them in the development of eptihelial-mesenchymal transition and metastasis ([@b76-molcell-37-4-275-1]). In HCC, high expression of the heparinsulfate proteoglycan glypican-3 (GPC3) on the surface of cancer cells is associated with increased Mϕ infiltration in human patients, and human/mouse xenograft transplantation with a GPC3-overexpressing cell line leads to infiltration by Mϕ expressing M2-specific markers ([@b139-molcell-37-4-275-1]; [@b140-molcell-37-4-275-1]). M2 TAMs worsen HCC both by promoting tumor growth and angiogenesis and by encouraging liver fibrosis through IL-13 and TGFβ secretion ([@b130-molcell-37-4-275-1]).

THERAPIES TARGETING MΦ POLARIZATION
===================================

Given that Mϕ play important roles in maintaining tissue homeostasis and fighting disease, polarized Mϕ subsets that specifically contribute to the pathogenesis or amelioration of various diseases present themselves as attractive targets for therapeutic intervention. Different therapeutic strategies include either targeting the polarized Mϕ themselves or manipulating the signaling pathways involved in the process of Mϕ polarization to a desirable outcome.

Bacterial biofilms that form on body surfaces or on surgical implants lead to chronic and recurrent infections, and are difficult to treat with antibiotics ([@b30-molcell-37-4-275-1]; [@b104-molcell-37-4-275-1]). Early, local administration of M1 Mϕ or the C5a receptor agonist EP67, which stimulates M1 polarization, significantly attenuated biofilm formation in a mouse model ([@b50-molcell-37-4-275-1]). Furthermore, treatment of established biofilms significantly reduced bacterial burden compared to antibiotic treatment, suggesting the potential of a therapeutic alternative ([@b50-molcell-37-4-275-1]). Microbes themselves may also prove to be useful sources of therapeutics that modulate Mϕ polarization. *In vitro* application of extracellular polysaccharide secreted by an oligotrophic bacteria found in Lop Nur Desert, *Bacillus* sp. LBP32, was found to limit LPS-induced inflammation in the Mϕ cell line RAW 264.7 by inhibiting NF-κB and JNK activation, and may prove useful in diseases characterized by excessive M1 polarization ([@b29-molcell-37-4-275-1]). Similarly, the small-molecule compound bis-*N*-norgliovictin isolated from the marine-derived endophytic fungus *S3-1-c* inhibits LPS-induced M1 polarization of RAW 264.7 cells and murine peritoneal Mϕ, and improves survival in mouse models of sepsis ([@b133-molcell-37-4-275-1]). As a proof of concept for treating inflammatory gastrointestinal diseases, a lab strain of *E. coli* was created that secretes a Herpes virus homolog of IL-10 *via* a Sec-dependent transporter construct. Viral IL-10 delivered in this manner was shown to activate STAT3 and suppress TNFα production in the J774.1 murine Mϕ cell line ([@b39-molcell-37-4-275-1]).

IKKβ, a downstream mediator of insulin resistance and activator of the NF-κB pathway (and therefore of M1 polarization), is inhibited by anti-inflammatory salicylates like aspirin, which attenuates hyperglycemia and hyperinsulinemia in obese rodents ([@b156-molcell-37-4-275-1]; [@b158-molcell-37-4-275-1]). Several small trials in patients with type 2 diabetes have demonstrated that treatment with salicylates results in a marked reduction of diabetic metabolic parameters and improved glycemic control ([@b141-molcell-37-4-275-1]).

Apolipoprotein A-I mimetics are a class of therapeutic molecules that attempt to modulate HDL to treat atherosclerosis and are the subject of extensive clinical and mechanistic study, as reviewed in [@b73-molcell-37-4-275-1]. Interestingly, the mimetic D4F also has potential for cancer therapy: D4F inhibits the M2-associated scavenger receptor CD204/SRA on TAMs, preventing metastatic spread ([@b98-molcell-37-4-275-1]).

Anticancer therapies also seek to convert protumoral M2 Mϕ into M1 Mϕ. M2 Mϕ generated by IL-6 and prostaglandin E2 secreted by cervical cancer cells can be repolarized to M1 by coculture with Th1 cells, and this interaction could possibly be reproduced by activation with CD40L and IFNγ ([@b53-molcell-37-4-275-1]). Moreover, IFNγ was shown to successfully switch M2 TAMs purified from human ovarian tumors to an M1 phenotype, and the addition of IFNγ skewed *de novo* tumor-induced M2 differentiation of monocytes to favor M1 polarization ([@b32-molcell-37-4-275-1]). Other potentially therapeutic molecules found to repolarize TAMs from an M2 to an M1 phenotype include zoledronic acid, CpG oligonucleotide, and histidine-rich glycoprotein ([@b22-molcell-37-4-275-1]; [@b57-molcell-37-4-275-1]; [@b118-molcell-37-4-275-1]).

CONCLUSION
==========

The integral importance of Mϕ in the maintenance of nearly every tissue throughout the body and their position as the first line of defense against many diseases guarantees that they play critical roles in both disease progression and in resolution, and that altering the behavior of these cells can mean the difference between healthy recovery and severe illness. Mϕ polarization itself is an extremely nuanced and fine-tuned process and can produce nearly infinite variations of endpoint phenotypes, each of which has the potential to affect various diseases in different ways. While polarized Mϕ subsets and the polarization process itself are attractive and novel therapeutic targets in both infectious and inflammatory disease, better understanding of how polarization is controlled and how polarized Mϕ modulate specific diseases is necessary to fully harness the potential of these strategies.
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![Schematic representation of Mϕ polarization. While M1/classically activated macrophages are typically induced by IFNγ and microbial products like LPS, different stimuli lead to the development of an array of finely tuned alternately activated states. IC, Immune complex; HH, Hapto-hemoglobin; OxRBC, oxidized red blood cells; Ox-PL-PPC, ox-PL 1-palmitoyl-2arachidonoyl-sn-glycero-3-phosphorycholine; FFA, free fatty acid.](molcell-37-4-275-1f1){#f1-molcell-37-4-275-1}

![Major signaling pathways involved in M1/M2 Mϕ polarization. STAT1/3 and STAT6 regulate transcription of M1 and M2 genes following recognition of IFNγ or IL-4/13 by their surface receptors and activation of JAKs (A). Differential activation of Akt1 or Akt2 *via* PI3K and PIP3 leads to either M2 or M1 polarization, respecively (B). Upon activation, the intracellular domain of Notch (NICD) is cleaved and activates IRF8 to promote M1 polarization. GM-CSF triggers M1 polarization *via* IRF5 while M-CSF induces M2 polarization *via* IRF4 (C).](molcell-37-4-275-1f2){#f2-molcell-37-4-275-1}

###### 

SR, scavenger receptor; MR, mannose receptor; HO-1, heme oxygenase-1; VEGF, vascular endothelial growth factor; SD-1, sulfiredocin-1; TR-reductase, thioredoxin-reductase ([@b62-molcell-37-4-275-1]; [@b72-molcell-37-4-275-1]; [@b95-molcell-37-4-275-1])

  Polarization state   Gene expression                                              Cytokines                                                      Chemokines
  -------------------- ------------------------------------------------------------ -------------------------------------------------------------- -----------------------------------------------------------------------------
  M1                   CD80, CD86, MHC I/II, IL-1R I, TLR2, TLR4, iNOS              TNFα, IL-1, IL-6, IL-12, IL-15, IL-23, ROS, iNOS, type I IFN   CXCL1-3, CXCL5, CXCL8-10, CXCL16, CCL2-5, CCL8, CCL11, CCL15, CCL20, CX3CL1
  M2a                  CD163, MHC II, SR, CD206, MR, IL-1R II, YM-1, Fizz1, Arg-1   IL-10, TGFβ, IL-12, IL-1Ra                                     CCL1, CCL2, CCL24, CCL22, CCL17, CCL18
  M2b                  CD86, MHC II                                                 IL-10, IL-1, TNFα, IL-6                                        CCL1, CCL20, CXCL1, CXCL2, CXCL3
  M2c                  CD163, TLR1, MR, Arg-1, YM-1, TLR8                           IL-10, TGFβ                                                    CCL16, CCL18
  M2d                  VEGF                                                         IL-10, VEGF                                                    CCL5, CXCL10, CXCL16
  M4                   ?                                                            TNFα                                                           CCL18, CCL20
  Mhem                 HO-1                                                         IL-10                                                          ?
  MOx                  HO-1, SD-1, TR-reductase                                     ?                                                              ?
